Conduit Pharmaceuticals Pipeline Update: AZD1656, AZD5658, & AZD5904
Conduit Pharmaceuticals announced progress in its preclinical and clinical pipeline, including studies for AZD5658 in lupus, Phase IIa trial...
Protara Therapeutics: Choline Deficiency and Liver Injury in Parenteral Support Patients: Encore Presentation of THRIVE-1 Results
Protara Therapeutics announced results from THRIVE-1, a study on choline deficiency and liver injury in patients dependent on parenteral...
Acumen Announces Results for Sabirnetug Formulation Study
Acumen Pharmaceuticals announced positive topline results from a Phase 1 study of its Alzheimer’s drug, sabirnetug. The study compared...
Arbor Biotechnologies Secures $73.9M Series C Funding for Gene Editing
Arbor Biotechnologies secured $73.9 million in Series C funding, led by ARCH Venture Partners and TCGX, to advance its...
Fruquintinib & Sintilimab Trial Meets Primary Endpoint in Advanced RCC
HUTCHMED and Innovent Biologics announced positive top-line results from the FRUSICA-2 Phase II/III trial. The trial investigated fruquintinib combined...
Ocu200 DME Trial: Cohort 2 Dosing Approved After Safety Review
Ocugen, a biotechnology company, announced positive safety data from the first cohort of its Phase 1 clinical trial for...
Clearmind Medicine Initiates First Human Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use...
Angitia Biopharmaceuticals Presents Promising Phase 1/2 Study Data of AGA111 at AAOS
Angitia Biopharmaceuticals announced positive Phase 1/2 trial data for AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6) designed...
Prime Medicine Unveils AATD Gene Correction Treatment Program
Prime Medicine announced a preclinical program for alpha-1 antitrypsin deficiency (AATD), using its prime editing technology delivered via a...
Bio-Path Holdings Announces Promising Pre-clinical Results for BP1001-A in Obesity Treatment for Type 2 Diabetes Patients
Bio-Path Holdings announced positive pre-clinical results for BP1001-A, a potential obesity treatment. The drug candidate successfully reversed fatty acid-induced...